Following these results, the Food and Drug Administration (FDA) and Europe Medicine Agency (EMA) approved the use of consolidation durvalumab following radical CRT as standard treatment, although the EMA limited its indication to tumours with PD-L1 expression (≥1%) based on a post hoc study of subgroups in which tumours without PD-L1 expression did not receive a significant benefit to survival, a situation that is highly debated within the scientific community. The gene discussed is CD274; the disease is neoplasm.